Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Articles
Articles
Personalizing Patient Management and Oral Adherence for the Oncology Patient
ASHP 2016
The role of the oncology pharmacist in promoting oral adherence for the oncology patient is discussed.
Read More ›
Latest Developments in Short-Acting Granulocyte Colony-Stimulating Factor (G-CSF) Treatment Options: The First FDA-Approved Biosimilar, Zarxio® (filgrastim-sndz)
ASHP 2016
Biosimilarity between Zarxio and Neupogen is proven through PIONEER study results.
Read More ›
IFCT-1001 CHIVA trial: A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)-associated advanced non-squamous non-small-cell lung cancer (NS-NSCLC)
ASCO 2016 – Lung Cancer
Read More ›
A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study
ASCO 2016 – Lung Cancer
Read More ›
A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13
ASCO 2016 – Lung Cancer
Read More ›
Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study
ASCO 2016 – Lung Cancer
Read More ›
An open-label phase 2 trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928)
ASCO 2016 – Lung Cancer
Read More ›
Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression
ASCO 2016 – Lung Cancer
Read More ›
Bayesian randomized trial comparing intensity-modulated radiation therapy versus passively scattered proton therapy for locally advanced non–small-cell lung cancer
ASCO 2016 – Lung Cancer
Read More ›
Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression
ASCO 2016 – Lung Cancer
Read More ›
Page 120 of 147
117
118
119
120
121
122
123
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us